Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection

References

• Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr. Respir. Rev.5(Suppl. A), S119–S126 (2004).
   PubMedGoogle Scholar
• Staat MA. Respiratory syncytial virus infections in children. Semin. Respir. Infect.17, 15–20 (2002).
   PubMedGoogle Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352, 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA283, 499–505 (2000).
   PubMed Web of Science ®Google Scholar
• Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med.171, 137–141 (2005).
   PubMed Web of Science ®Google Scholar
• You D, Becnel D, Wang K, Ripple M, Daly M, Cormier SA. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir. Res.7, 107 (2006).
   PubMed Web of Science ®Google Scholar
• Aherne W, Bird T, Court SDM, Gardner PS, McQuillin J. Pathological changes in virus infections of the lower respiratory tract in children. J. Clin. Pathol.23, 7–18 (1970).
   PubMed Web of Science ®Google Scholar
• Everard ML, Swarbrick A, Wrightham M et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch. Dis. Child.71, 428–432 (1994).
   PubMed Web of Science ®Google Scholar
• Nelson KA, Yunis EJ. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr. Pathol.10, 491–502 (1990).
   PubMedGoogle Scholar
• Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev.18, 541–555 (2005).
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med.186, 421–432 (1997).
   PubMed Web of Science ®Google Scholar
• Braciale TJ. Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system. Proc. Am. Thorac. Soc.2, 141–146 (2005).
   PubMedGoogle Scholar
• Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis.195, 1126–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Culley FJ, Pennycook AM, Tregoning JS et al. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J. Virol.80, 4521–4527 (2006).
   PubMed Web of Science ®Google Scholar
• Kristjansson S, Bjarnarson SP, Wennergren G et al. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J. Allergy Clin. Immunol.116, 805–811 (2005).
   PubMed Web of Science ®Google Scholar
• Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. Immunol.2, 106–115 (2002).
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol.18, 217–242 (2000).
   PubMed Web of Science ®Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol.17, 657–700 (1999).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 α, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. J. Respir. Crit. Care Med.156, 1377–1383 (1997).
   PubMed Web of Science ®Google Scholar
• Ying S, Meng Q, Zeibecoglou K et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J. Immunol.163, 6321–6329 (1999).
   PubMed Web of Science ®Google Scholar
• Pilette C, Francis JN, Till SJ, Durham SR. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur. Respir. J.23, 876–884 (2004).
   PubMed Web of Science ®Google Scholar
• Bochner BS, Hudson SA, Xiao HQ, Liu MC. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. J. Allergy Clin. Immunol.112, 930–934 (2003).
   PubMed Web of Science ®Google Scholar
• Hartl D, Griese M, Nicolai T et al. A role for MCP-1/CCR2 in interstitial lung disease in children. Respir. Res.6, 93 (2005).
   PubMed Web of Science ®Google Scholar
• Moore BB, Paine R 3rd, Christensen PJ et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol.167, 4368–4377 (2001).
   PubMed Web of Science ®Google Scholar
• Huaux F, Gharaee-Kermani M, Liu T et al. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am. J. Pathol.167, 1485–1496 (2005).
   PubMed Web of Science ®Google Scholar
• Petrek M, Kolek V, Szotkowska J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur. Respir. J.20, 1206–1212 (2002).
   PubMed Web of Science ®Google Scholar
• Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev.14, 467–477 (2003).
   PubMed Web of Science ®Google Scholar
• Wickremasinghe MI, Thomas LH, O’Kane CM, Uddin J, Friedland JS. Transcriptional mechanisms regulating alveolar epithelial cell-specific CCL5 secretion in pulmonary tuberculosis. J. Biol. Chem.279, 27199–27210 (2004).
   PubMed Web of Science ®Google Scholar
• Chakravarty SD, Xu J, Lu B, Gerard C, Flynn J, Chan J. The chemokine receptor CXCR3 attenuates the control of chronic Mycobacterium tuberculosis infection in BALB/c mice. J. Immunol.178, 1723–1735 (2007).
   PubMed Web of Science ®Google Scholar
• Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol. Sci.27, 546–553 (2006).
   PubMed Web of Science ®Google Scholar
• Tomaki M, Sugiura H, Koarai A et al. Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung. Pulm. Pharmacol. Ther.11, 11 (2006).
   Google Scholar
• Traves SL, Smith SJ, Barnes PJ et al. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J. Leukoc. Biol.76, 441–450 (2004).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Ramos JC, Lloyd C, Kapsenberg ML, Gonzalo JA, Coyle AJ. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol. Rev.177, 31–42 (2000).
   PubMed Web of Science ®Google Scholar
• Drews J. Drug discovery: a historical perspective. Science287, 1960–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Neel NF, Schutyser E, Sai J, Fan GH, Richmond A. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev.16, 637–658 (2005).
   PubMed Web of Science ®Google Scholar
• Di Marzio P, Dai WW, Franchin G, Chan AY, Symons M, Sherry B. Role of Rho family GTPases in CCR1- and CCR5-induced actin reorganization in macrophages. Biochem. Biophys. Res. Commun.331, 909–916 (2005).
   PubMed Web of Science ®Google Scholar
• Wain JH, Kirby JA, Ali S. Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. Clin. Exp. Immunol.127, 436–444 (2002).
   PubMed Web of Science ®Google Scholar
• Shyamala V, Khoja H. Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells. Biochemistry37, 15918–15924 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur. Respir. J.25, 1084–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Coffer PJ, Schellens IM, de Graaff PM, Kimpen JL, Koenderman L. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-κB-dependent mechanism. J. Immunol.176, 5529–5537 (2006).
   PubMed Web of Science ®Google Scholar
• Hirsch E, Katanaev VL, Garlanda C et al. Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation. Science287, 1049–1053 (2000).
   PubMed Web of Science ®Google Scholar
• Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol.3, 426–434 (2003).
   PubMed Web of Science ®Google Scholar
• Le Y, Cui Y, Iribarren P, Ying G, Wang JM. Manipulating chemoattractant and receptor genes. In Vivo16, 1–23 (2002).
   PubMed Web of Science ®Google Scholar
• Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother.16, 339–354 (2005).
   PubMedGoogle Scholar
• Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs65, 879–904 (2005).
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother.49, 4721–4732 (2005).
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med.11, 1170–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Strizki JM, Tremblay C, Xu S et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother.49, 4911–4919 (2005).
   PubMed Web of Science ®Google Scholar
• Huff B. HIV co-receptor drugs on the horizon. GMHC Treat. Issues18, 7–8 (2004).
   PubMedGoogle Scholar
• Schols D. HIV co-receptors as targets for antiviral therapy. Curr. Top. Med. Chem.4, 883–893 (2004).
   PubMed Web of Science ®Google Scholar
• Wegmann M, Goggel R, Sel S et al. Effect of a low molecular weight CCR-3 antagonist on chronic experimental asthma. Am. J. Respir. Cell Mol. Biol.17, 17 (2006).
   Google Scholar
• Nakamura T, Ohbayashi M, Toda M, Hall DA, Horgan CM, Ono SJ. A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol. Res.33, 213–221 (2005).
   PubMed Web of Science ®Google Scholar
• De Lucca GV. Recent developments in CCR3 antagonists. Curr. Opin. Drug Discov. Devel.9, 516–524 (2006).
   PubMedGoogle Scholar
• Morokata T, Suzuki K, Masunaga Y et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J. Pharmacol. Exp. Ther.317, 244–250 (2006).
   PubMed Web of Science ®Google Scholar
• Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol.160, 1353–1360 (2002).
   PubMed Web of Science ®Google Scholar
• Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest123, 1240–1247 (2003).
   PubMed Web of Science ®Google Scholar
• Yang XD, Corvalan JR, Wang P, Roy CM, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol.66, 401–410 (1999).
   PubMed Web of Science ®Google Scholar
• Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest126, 926–934 (2004).
   PubMed Web of Science ®Google Scholar
• Becker S, Soukup JM. Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection. Immunobiology201, 88–106 (1999).
   PubMed Web of Science ®Google Scholar
• Becker S, Reed W, Henderson FW, Noah TL. RSV infection of human airway epithelial cells causes production of the β-chemokine RANTES. Am. J. Physiol.272, L512–L520 (1997).
   PubMed Web of Science ®Google Scholar
• McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J. Infect. Dis.191, 1225–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Noah TL, Ivins SS, Murphy P, Kazachkova I, Moats-Staats B, Henderson FW. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin. Immunol.104, 86–95 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luxon BA, Casola A, Garofalo RP, Jamaluddin M, Brasier AR. Expression of respiratory syncytial virus-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J. Virol.75, 9044–9058 (2001).
   PubMed Web of Science ®Google Scholar
• Welliver RC, Garofalo RP, Ogra PL. β-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr. Infect. Dis. J.21, 457–461 (2002).
   PubMed Web of Science ®Google Scholar
• Sheeran P, Jafri H, Carubelli C et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr. Infect. Dis. J.18, 115–122 (1999).
   PubMed Web of Science ®Google Scholar
• Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo.J. Infect. Dis.189, 1419–1430 (2004).
   PubMed Web of Science ®Google Scholar
• Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1α (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J. Infect. Dis.184, 393–399 (2001).
   PubMed Web of Science ®Google Scholar
• Tekkanat KK, Maassab H, Miller A, Berlin AA, Kunkel SL, Lukacs NW. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur. J. Immunol.32, 3276–3284 (2002).
   PubMed Web of Science ®Google Scholar
• Culley FJ, Pennycook AM, Tregoning JS et al. Role of CCL5 (RANTES) in viral lung disease. J. Virol.80, 8151–8157 (2006).
   PubMed Web of Science ®Google Scholar
• Trifilo MJ, Bergmann CC, Kuziel WA, Lane TE. CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection. J. Virol.77, 4004–4014 (2003).
   PubMed Web of Science ®Google Scholar
• Miller AL, Strieter RM, Gruber AD, Ho SB, Lukacs NW. CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J. Immunol.170, 3348–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Miller AL, Gerard C, Schaller M, Gruber AD, Humbles AA, Lukacs NW. Deletion of CCR1 attenuates pathophysiologic responses during respiratory syncytial virus infection. J. Immunol.176, 2562–2567 (2006).
   PubMed Web of Science ®Google Scholar
• Morrison PT, Thomas LH, Sharland M, Friedland JS. RSV-infected airway epithelial cells cause biphasic up-regulation of CCR1 expression on human monocytes. J. Leukoc. Biol. DOI: 10.1189/jlb.1006611 (2007).
   PubMed Web of Science ®Google Scholar
• Patel H, Platt R, Lozano JM et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst. Rev.CD004878 (2004).
   Google Scholar
• Rodriguez WJ, Arrobio J, Fink R et al. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Ribavirin Study Group. Arch. Pediatr. Adolesc. Med.153, 469–474 (1999).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89, 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Polack FP, Karron RA. The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J.23, S65–S73 (2004).
   Web of Science ®Google Scholar
• Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst. Rev.CD004883 (2006).
   Google Scholar
• IMpact-RSV-Study-Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics102, 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost–effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J. Paediatr. Child Health42, 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur. Respir. J.29, 91–97 (2007).
   PubMed Web of Science ®Google Scholar
• Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5). J. Med. Virol.73, 300–308 (2004).
   PubMed Web of Science ®Google Scholar
• Hull J, Rowlands K, Lockhart E, Moore C, Sharland M, Kwiatkowski D. Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J. Infect. Dis.188, 904–907 (2003).
   PubMed Web of Science ®Google Scholar
• Vaidehi N, Schlyer S, Trabanino RJ et al. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J. Biol. Chem.281, 27613–27620 (2006).
   PubMed Web of Science ®Google Scholar
• Gladue RP, Cole SH, Roach ML et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J. Immunol.176, 3141–3148 (2006).
   PubMed Web of Science ®Google Scholar
• Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J. Virol.79, 2050–2057 (2005).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol.2, 732–738 (2001).
   PubMed Web of Science ®Google Scholar
• Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol.176, 1600–1608 (2006).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones L, Anderson LJ. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol.74, 6227–6229 (2000).
   PubMed Web of Science ®Google Scholar
• Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C–CX3CR1 interaction and expression of substance P. J. Virol.77, 9831–9844 (2003).
   PubMed Web of Science ®Google Scholar
• Amanatidou V, Sourvinos G, Apostolakis S, Tsilimigaki A, Spandidos DA. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr. Infect. Dis. J.25, 410–414 (2006).
   PubMed Web of Science ®Google Scholar
• Streit WJ, Davis CN, Harrison JK. Role of fractalkine (CX3CL1) in regulating neuron-microglia interactions: development of viral-based CX3CR1 antagonists. Curr. Alzheimer Res.2, 187–189 (2005).
   PubMedGoogle Scholar
• Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J. Pediatr.89, 11–15 (1976).
   PubMed Web of Science ®Google Scholar
• Bonville CA, Lau VK, DeLeon JM et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo.J. Virol.78, 7984–7989 (2004).
   PubMed Web of Science ®Google Scholar
• van Benten IJ, van Drunen CM, Koopman LP et al. Age- and infection-related maturation of the nasal immune response in 0–2-year-old children. Allergy60, 226–232 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas LH, Sharland M, Friedland JS. Steroids fail to down-regulate respiratory syncytial virus-induced IL-8 secretion in infants. Pediatr. Res.52, 368–372 (2002).
   PubMed Web of Science ®Google Scholar